Sillajen

Our primary Phase III clinical study in hepatic cancer, known as the “PHOCUS”, is making efficient progress. We anticipate obtaining the Futility Analysis outcome this year, which holds significant importance as the initial clinical result from PHOCUS. Concurrently, this analysis will strengthen the reliability and prospects of Pexa-Vec in the international market. This year, SillaJen was thrilled to expand the Clinical Department, enhancing our primary focus area. To advance to the next stage, it is essential to broaden the pipeline to encompass additional tumor types.